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Interferon score is increased in incomplete
systemic lupus erythematosus and
correlates with myxovirus-resistance
protein A in blood and skin
Wietske M. Lambers1* , Karina de Leeuw1, Berber Doornbos-van der Meer1, Gilles F.H. Diercks2,
Hendrika Bootsma1 and Johanna Westra1
Abstract
Objectives: Patients with incomplete systemic lupus erythematosus (iSLE) have lupus features, but do not meet
classification criteria for SLE. Type I interferons (IFN) are important early mediators in SLE, and IFN upregulation in
incomplete SLE may be associated with progression to SLE. Since many patients present with skin symptoms, the
aim of this study is to investigate IFN type I expression and IFN-related mediators in the blood and skin of iSLE
patients.
Methods: Twenty-nine iSLE patients (ANA titer ≥ 1:80, symptoms < 5 years, ≥ 1 objectified clinical criterion), 39 SLE
patients with quiescent disease (fulfilling ACR or SLICC criteria, SLEDAI ≤4), and 22 healthy controls were included.
IFN signature was measured in whole blood, based on 12 IFN-related genes, using RT-PCR, and IFN-score was
calculated. IFN-related mediators myxovirus-resistance protein A (MxA), IFN-γ-induced protein 10 (IP-10), and
monocyte chemoattractant protein (MCP-1) were measured using ELISA. IFN type I expression in the unaffected
skin was analyzed by immunostaining with MxA.
Results: IFN-score was increased in 50% of iSLE patients and 46% of SLE patients and correlated positively with the
number of autoantibodies, anti-SSA titer, ESR, and IgG and negatively with C4 in iSLE. Levels of MxA correlated
strongly with IFN-score (r = 0.78, p < 0.0001). Furthermore, MxA expression was found in 29% of unaffected skin
biopsies of iSLE and 31% of SLE patients and also correlated with IFN-score (r = 0.54, p < 0.0001).
Conclusions: IFN-score was increased in half of the iSLE patients, and given the correlation with complement and
autoantibody diversity, this suggests a higher risk for disease progression. MxA in the blood and unaffected skin
correlated strongly with the IFN-score and is possibly an easily applicable marker for IFN upregulation.
Keywords: Systemic lupus erythematosus, Interferon signature, Myxovirus resistance protein A, Biomarker
Introduction
Systemic lupus erythematosus (SLE) is a prototypic auto-
immune disease that is characterized by formation of an-
tinuclear antibodies (ANA) and inflammation of various
organ systems [1]. Despite the progress in understanding
the pathogenesis of SLE and the subsequent increase in
treatment options, disease burden is still high [2]. A fre-
quent diagnostic delay, attributable to the heterogeneous
clinical picture, is one of the main reasons for damage
accrual [3].
Although clinical expert opinion is still the gold stand-
ard for SLE diagnosis, classification criteria have been
developed for scientific purposes. The criteria developed
by the American College of Rheumatology (ACR) and
updated in 1997 are most widely used [4, 5]. In 2012,
new classification criteria were introduced by the
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Systemic Lupus International Collaborating Clinics
(SLICC) group in order to improve clinical relevance
and to incorporate new knowledge regarding the patho-
genesis of SLE [6]. Very recently, new EULAR/ACR clas-
sification criteria for SLE have been published [7].
A subgroup of lupus patients displays clinical symp-
toms or immunologic abnormalities that are typical for
SLE, but do not fulfill the classification criteria. This
condition is referred to as “incomplete systemic lupus
erythematosus” (iSLE). Some of these patients remain in
a clinically stable state of limited disease, but 10–55%
develop SLE [8–11]. Investigating incomplete SLE is of
interest, since it could provide insight in disease patho-
genesis and possibly reveal predictive biomarkers for
SLE. Consequently, stratifying the risk for disease pro-
gression will allow less frequent follow-up for low-risk
patients, while on the other hand high-risk patients can
be monitored more closely, and possibly start treatment
earlier.
Although the precise pathophysiology of SLE is com-
plex and has not been fully elucidated yet, IFN-alpha,
which is a type I IFN, has been demonstrated to be an
important early mediator [12]. Last year, Yusof et al.
showed that IFN gene upregulation in patients with
ANA positivity and at least one SLICC criterion was as-
sociated with progression to SLE [13]. Plasmacytoid den-
dritic cells (pDCs) are the most potent producers of
IFN-alpha and respond to binding of RNA- and DNA-
containing autoimmune complexes to Fcγ receptors on
the cell surface. Subsequent activation of endosomal
toll-like receptors (TLRs) 7 and -9 results in the produc-
tion of large amounts of IFN-alpha [14]. This cytokine
supports differentiation, proliferation, and survival of T
and B cells and hence enhances production of more
autoantibodies resulting in a feed-forward loop [15–17].
As it is rather difficult to measure IFN-alpha in serum
due to low levels and short lifetime, expression of IFN-
regulated genes is usually measured instead. Most SLE
patients show increased expression of IFN-regulated
genes in peripheral blood mononuclear cells or whole
blood, which is referred to as IFN signature [12, 18]. Fol-
lowing modular transcript analysis, IFN-regulated genes
are distributed over three gene modules (M1.2, M3.4,
and M5.12) [19]. Module 1.2 is mainly induced by IFN
type I and is stable over time, while the latter two—that
are sequentially activated—are induced by both IFN type
I and II and were previously shown to correlate with dis-
ease activity longitudinally [20].
As measuring IFN signature is time consuming, there is
a need for easily applicable markers for IFN expression.
Myxovirus-resistance protein A (MxA) is strictly induced
by IFN type I and a recent study showed strong robust
correlation with IFN gene upregulation [21]. Furthermore,
interferon-inducible chemokines IFN-γ-induced protein
10 (IP-10) and monocyte chemoattractant protein 1
(MCP-1) could be suitable as surrogate markers [22].
Likely, initiation of autoimmunity takes place in tissue
and not only in the circulation. Therefore, it was decided
to additionally analyze MxA in the skin. MxA is already
known to be expressed in active lupus skin lesions [23].
Skin is accessible for biopsy and relevant as up to 80% of
SLE patients will develop skin symptoms. Furthermore,
IFN type I plays a role in the formation of lupus skin le-
sions [24, 25].
The aim of the current study is to assess IFN gene ex-
pression and levels of IFN-related mediators in both cir-




Patients with iSLE were identified by screening the diag-
nosis registration system of our tertiary referral center
for “incomplete lupus,” “cutaneous lupus,” and “immune
disease not specified.” iSLE was defined as (1) ANA-titer
≥ 1:80; (2) one other objective clinical ACR criterion for
SLE, but not meeting ACR criteria or SLICC criteria;
and (3) disease manifestations < 5 years. Use of hydroxy-
chloroquine (HCQ) was allowed, but iSLE patients using
steroids or other immunosuppressants were excluded in
order to avoid treatment effects. SLE patients with clin-
ically quiescent disease (SLE daily activity index (SLE-
DAI) score ≤ 4) were selected as positive controls. All
SLE patients fulfilled ACR or SLICC criteria, and all had
disease duration < 10 years and the use of immunosup-
pressants in this patient group was allowed. During the
out-patient visit, additional blood was withdrawn and a
skin biopsy was taken. Results were compared to healthy
controls (HC), matched for age and gender with a ratio
of 3:1 (iSLE versus HC).
The research protocol was approved by the Institu-
tional Medical Ethical Committee (METc 2015/313). All
subjects provided written informed consent.
Laboratory investigations
All clinical data and standard laboratorial measurements
were retrieved from medical records. Antinuclear antibodies
(ANA) were measured by indirect immunofluorescence
technique using Hep2-cells as substrate. Anti-double-
stranded DNA antibodies (anti-dsDNA) and other autoanti-
bodies were measured using the automated EliA assay (ENA
CTD screen, Thermo Fisher Scientific, Nieuwegein, the
Netherlands).
Interferon signature
Whole blood samples were collected in PAXgene RNA
tubes and stored at − 20 °C. After thawing, RNA was
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isolated using PAXgene Blood RNA Kit (Cat No./ID:
762164).
Isolated RNA was reversely transcribed to cDNA and
subsequently quantitatively analyzed using an Applied
Biosystems™ QuantStudio™ 6 Flex Real-Time PCR Sys-
tem. Relative expression (RE) was calculated based on
the cycle threshold (Ct) value related to expression of
the housekeeping gene GAPDH as follows: RE = 2-(Ct Test
gene − Ct GAPDH). The Ct value of GAPDH was confirmed
to be stable in all performed analyses in all cohorts.
Twelve IFN-related transcripts were determined,
representing all three IFN modules (M1.2: IP10, IFI44L,
IFIT3, LY6E, MX1, and SERPING1; M3.4: IFITM1,
IRF7, and STAT1; M5.12: C1QA, IFI16, and IRF9) [20].
In order to construct a workable unity to compare gene
expression between individuals, an IFN-score was gener-
ated. The IFN-score was calculated by summing up the
individual RE per gene after normalization to the control
group as follows: ∑(REsubject − Meanhc)/SDhc [26]. Re-
garding the three interferon modules, a separate gene
score was calculated, based on the genes from the con-
cerning module (M1.2, M3.4, and M5.12). In order to in-
crease comparability with other studies, an IFN3-score
was composed, based on the sum of normalized RE of
three widely used IFN genes (IFI44L, LY6E, and MX1).
An IFN-score was regarded positive when it was higher
than the mean + 2SD of HC values. In one iSLE patient,
Paxgene tubes were not available; therefore, this patient
could not be included in IFN gene measurements.
IFN-related mediators
Levels of serum IP-10 and MCP-1 were measured by
ELISA (Duoset, R&Dsystems, Minneapolis, Canada).
High-performance ELISA buffer (Sanquin, Amsterdam,
the Netherlands) was used during serum incubation to
prevent non-specific reactions.
Levels of MxA were measured by ELISA in lysed
whole blood as described previously [27]. Intra- and
inter-assay variation of this ELISA was 7% and 6%,
respectively.
Cut-off levels were determined based on the mean +
2SD of the control group, resulting in the values of 94.5
pg/mL for IP-10, 391.2 pg/mL for MCP-1, and 55.9 ng/
mL for MxA.
Skin biopsy analysis
Subjects underwent biopsy of 4-mm unaffected and
non-sunexposed skin from the buttock. Skin biopsies
were formalin-fixed and embedded in paraffin.
Sections were deparaffinized, and antigen retrieval was
performed with tris-HCl and EDTA. Goat-anti human
MxA (R&D, AF7946, Minneapolis, Canada) was added
overnight; consecutively, samples were incubated with
rabbit anti-goat-HRP conjugate (Dako, 0449, Santa
Clara, USA) and stained with diaminobenzidine (DAB)
colorant (Dako K4006, Santa Clara, USA).
Control staining with the addition of secondary anti-
body alone and using normal goat serum was negative.
A positive control of the lesional lupus skin showed
strong MxA expression throughout all dermal structures
(see Additional file 1: Figure S1). Scoring of MXA ex-
pression was done by a team of a pathologist and two in-
vestigators. The samples were blinded. The expression
of MxA was scored semi-quantitatively for separate
structures, namely the epidermis, endothelium, adnexa,
fibroblasts, and infiltrates, as follows: “0” for no expres-
sion, “0.5” for weak expression, “1” for moderate expres-
sion, “2” for intermediate expression, and “3” for strong
expression.
Statistical analysis
Comparison between groups was performed using
Mann-Whitney U test for continuous data and chi-
square test for dichotomous variables. Correlations were
calculated using Spearman r test. Correlations and group
comparison were calculated for a minimum of 5 sub-
jects. Analyses were carried out using IBM SPSS Statis-




Patient characteristics and cumulative disease character-
istics are shown in Table 1. The vast majority of patients
were Caucasian. Median age of iSLE and SLE patients
was 43 and 44 years respectively. As expected, iSLE dis-
ease duration was shorter (1.4 versus 2.8 years). Current
disease features and laboratory measurements are shown
in Table 2.
IFN gene expression
The IFN-score based on 12 genes (IFN12-score) was in-
creased in 14 (50%) iSLE patients and 18 (46%) SLE pa-
tients (Fig. 1a).
The patient groups were divided into IFN high and
IFN normal according to IFN expression. Characteristics
are shown in Table 3. In iSLE, there were no differences
regarding clinical symptoms among IFN-high patients
and IFN-normal patients. Increased IFN12-score in iSLE
patients was not associated with a higher number of cu-
mulative classification criteria, neither with disease dur-
ation or SLEDAI. iSLE patients who used HCQ—all
patients had therapeutic levels—had similar IFN12-
scores as those who did not use this drug. IFN-high iSLE
patients however had higher ESR (p = 0.004), more anti-
body diversity (p = 0.04), lower C3 (p = 0.01), and C4
(p = 0.002), as well as increased total IgG (p = 0.04).
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SLE patients with increased IFN12-scores more often
had skin involvement (p = 0.006) and alopecia (p = 0.01),
more frequently had anti-Smith antibodies (p = 0.05),
and had higher SLEDAI scores (p = 0.03). There was no
difference in medication use between the IFN-high and
IFN-normal SLE patients. Regarding serological tests,
IFN-high patients had lower neutrophil counts (p = 0.03)
and lower C3 levels (p = 0.01).
Correlations between IFN12-score and continuous
variables revealed no remarkable other findings than
when comparing IFN high versus normal (see Add-
itional file 1: Table S2 and Figure S2).
Next, IFN expression was analyzed for each IFN-
related module separately (Fig. 1c–e). Among iSLE pa-
tients, an increased IFN-M1.2 score was seen in 54%,
IFN-M3.4 was increased in 36%, and IFN-M5.12 was
increased in 18% (Fig. 1c–e). The modular IFN-scores
correlated strongly with each other, as with the overall
IFN12-score, with r values > 0.8 and p values < 0.0001.
At last, the IFN-score based on IFI44L, LY6E, and
MX1, 3 commonly used genes (IFN3-score) was calcu-
lated. Upregulation was found in 14 (50%) iSLE patients
and 20 (51%) SLE patients (Fig. 1b). Correlations were
almost identical for IFN3-score compared to IFN12-
score (see Additional file 1: Tables S1 and S2).
Levels of IFN-related soluble mediators and correlations
with clinical parameters
MxA levels were increased in 20 (69%) of iSLE patients
(median 77.5 ng/mL) and 29 (74%) of SLE patients (me-
dian 72.6 ng/mL) (Fig. 2a). In iSLE, MxA levels corre-
lated positively with ESR (r = 0.50, p = 0.005), anti-SSA
Table 1 Baseline characteristics
HC (n = 22) iSLE (n = 29) SLE (n = 39) p value
Female gender, n (%) 18 (82) 23 (79) 32 (82) NS
Age (years) 45 (24–65) 44 (20–83) 43 (19–76) NS
Race, n (%)
Caucasian 100 25 (86) 35 (90)
Asian 0 2 (7) 1 (3)
Other 0 2 (7) 3 (8)
Disease duration (years) 1.4 (0.1–4.6) 2.8 (0.5–6.8) 0.004
ACR criteria 3 (1–3) 5 (2–9) < 0.0001
SLICC criteria 3 (2–4)* 5 (3–9) < 0.0001
Clinical criteria, n (%)
Skin involvement 13 (45) 21 (54) 0.46
Photosensitivity 3 (10) 9 (23) 0.17
Arthritis 6 (21) 18 (46) 0.03
Alopecia 0 5 (13) 0.05
Ulcera 1 (3) 6 (15) 0.11
Hematologic 11 (38) 26 (67) 0.02
Serositis 2 (7) 9 (23) 0.07
Renal 0 13 (33) 0.001
Neurologic 1 (3)** 2 (5) 0.48
Immunologic criteria, n (%)
ANA 3 (14) 29 (100) 39 (100) NA
Anti-dsDNA 0 9 (31) 32 (82) < 0.0001
Anti-SSA 0 13 (45) 13 (33) 0.59
Anti-Smith 0 2 (7) 6 (15) 0.28
Decreased complement 2 (9) 4 (14) 25 (64) < 0.0001
Antiphospholipid Ab 0 7 (24) 17 (44) 0.01
Coombs positive NA 4/23 (17) 7/17 (41) 0.10
*One patient had 4 immunologic SLICC criteria, but no clinical criterion
**Small fiber neuropathy not otherwise explained
For continuous data, median (range) are shown. p values of nominal variables are calculated for comparison of iSLE and SLE using chi-square test and continuous
variables by using Mann-Whitney U test. p values < 0.05 are indicated by italic font
Abbreviations: ANA antinuclear antibody, anti-dsDNA anti-double-stranded DNA, Ab antibodies, NS non-significant, NA not available
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Table 2 Clinical and serological features at the time of inclusion
HC (n = 22) iSLE (n = 29) SLE (n = 39)
SLEDAI (median, range) NA 0 (0–6) 2 (0–4)
Presence of clinical symptoms (n, %) NA
Active cutaneous lupus 5 (17) 4 (10)
Photosensitivity 9 (31) 8 (21)
Arthritis 1 (3) 0
Alopecia 0 0
Objectified ulcera 0 1 (3)
Hematologic features 11 (38) 19 (49)
Serositis 0 0
Renal features 0 1 (3)
Neurologic features 2 (7) 0
Laboratory results
ANA titer 40 (40–160) 160 (40–640*)• 80 (40–640*)•
Anti-dsDNA positive (n, %) 0 8 (28) 16 (41)
Anti-SSA positive (n, %) 0 12 (41) 12 (31)
Anti-Smith positive (n, %) 0 1 (3) 5 (13)
Anti-U1RNP (n, %) 0 2 (7) 5 (13)
Decreased complement (n, %) 0 6 (21) 15 (39)
Antiphospolipid antibodies (n, %) 0 10 (35) 12 (31)
ESR (mm/h) 5 (1–15) 19 (3–51)• 14 (3–96)•
Hb (mmol/) 8.20 (7.5–9.1) 8.3 (7.0–9.4) 8.0 (6.2–9.8)
Leukocytes (×109/L) 5.20 (4.5–7.4) 6.0 (2.6–9.2) 5.5 (2.3–11.9)
Lymphocytes (×109/L) 1.8 (1.3–2.9) 1.6 (0.5–3.2)‡ 1.2 (0.3–3.1)•
Thrombocytes (×109/L) 226 (184–363) 241 (135–406) 230 (112–369)
CRP (mg/L) 0.8 (0.3–3.3) 2.4 (0.3–24)• 1.7 (0.3–37)
GFR (mL/min) 98 (76–115) 91 (53–121) 91.5 (48–123)
C3 (g/L) 1.05 (0.68–1.23) 1.07 (0.04–1.47) 1.01 (0.54–1.37)
C4 (g/L) 0.16 (0.10–0.28) 0.20 (0.07–0.38)‡ 0.16 (0.05–0.34)
IgM (g/L) 1.3 (0.40–1.90) 0.95 (0.20–3.20) 0.7 (0.4–5.1)
IgG (g/L) 11.4 (8.9–16.1) 12.7 (7.2–25.4) 11.4 (5.0–19.5)
Drugs, n (%) NA
Hydroxychloroquine 9 (31) 33 (85)
NSAID 8 (29) 7 (18)
Prednisolone 0 12 (31)
Dose (median, range) 0 7.5 (5–10)
Mycophenolate 0 10 (26)
Azathioprine 0 6 (15)
Methotrexate 0 2 (5)
•p value < 0.05 comparing with HC
‡p value < 0.05 comparing with SLE
*ANA titers higher than 640 and SSA titers higher than 240 were not further diluted
For continuous data, median (range) are shown. p values of nominal values are calculated using chi-square test and continuous values using Mann-Whitney U test
Abbreviations: NA not applicable, ANA antinuclear antibody, Anti-dsDNA anti-double-stranded DNA, SLEDAI systemic lupus erythematosus disease activity index, ESR
erythrocyte sedimentation rate, NSAID non-steroid anti-inflammatory drug
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titer (r = 0.47, p = 0.01), and number of autoantibodies
(r = 0.47, p = 0.01) and negatively with C3 levels (r = −
0.42, p = 0.02) and C4 (r = − 0.40, p = 0.03) (see also Add-
itional file 1: Table 3).
IP-10 levels were increased in 9 (31%) of iSLE patients
(median 76.9 pg/mL) and 20 (36%) of SLE patients (me-
dian 65.7 pg/mL) (Fig. 2b). In iSLE, IP-10 levels corre-
lated with the number of ACR criteria (r = 0.38, p = 0.04)
and SLICC criteria (r = 0.37, p = 0.05) and negatively
with C3 levels (r = − 0.37, p = 0.05).
MCP-1 levels were increased in 4 (14%) iSLE patients
(median 288 pg/mL) and 10 (39%) SLE patients (median
311 pg/mL), but were not significantly higher than HC
(Fig. 2c).
IFN-related soluble mediators—surrogate marker
The relationship between IFN-related soluble mediators and
IFN-score was analyzed in the combined patient groups
(iSLE and SLE). Interestingly, MxA correlated strongly with
IFN12-score (r= 0.78, p < 0.0001) and IFN3-score (r= 0.81,
p < 0.0001) (Fig. 2d, g). The receiver operator characteristic
(ROC) curve for MxA shows an area under the curve
(AUC) of 0.94 (95% CI 0.88–1.0) for the IFN12-score and
0.94 (95% CI 0.87–1.0) for the IFN3-score (Fig. 3a, b). IP-10
levels were weakly correlated with the IFN12-score (r= 0.39,
p= 0.001) and with the IFN3 gene-score (r= 0.43, p= 0.003)
(Fig. 2e, h). The ROC curve for IP-10 showed an AUC of
0.68 (95% CI 0.55–0.81) for the IFN12-score and an AUC of
0.65 (95% CI 0.52–0.78) (Fig. 3c, d). MCP-1 levels were not
correlated with IFN-scores (Fig. 2f, i).
The tested mediators correlated with each other: MxA
and IP-10 (r = 0.48, p = 0.004), MxA and MCP-1 (r = 0.26,
p = 0.03), and IP-10 and MCP-1 (r = 0.35, p = 0.004).
MxA expression in the skin
MxA staining was performed in sections of 9 HC, 24
iSLE patients, and 32 SLE patients. Results are shown in
Fig. 4. Some of the HC slides showed moderate MxA ex-
pression; therefore, intermediate MxA expression or
stronger (score ≥ 2) was regarded positive. MxA expres-
sion was most frequently seen in the endothelium and
was positive in 7 of 24 (29%) biopsies of iSLE patients
and 10 of 32 (31%) of SLE patients. The adnexa and epi-
dermis were positive in 3 of 24 (13%) of iSLE patients
and 3 of 32 (9.4%) of SLE patients. These structures
were only positive when MxA was also expressed in the
endothelium. MxA staining of fibroblasts was positive in
only 2 of 24 (8%) iSLE patients and 2 of 32 (6.2%) SLE
patients. Infiltrates were almost not present, except in
one SLE patient. Because of the limited numbers of posi-
tive stainings in the epidermis, adnexa, infiltrates, and fi-
broblasts, these results were not analyzed.
MxA expression in the skin endothelium of iSLE pa-
tients correlated positively with whole blood MxA levels
Fig. 1 IFN-scores in all subject groups. IFN12-score (a), IFN3-score (b), and IFN-M1.2, IFN-M3.4, and IFN-M5.12 scores (c–e). The dotted line
represents mean + 2SD of the HC. The percentages represent the proportion of patients above this line. Abbreviations: HC healthy controls, iSLE
incomplete systemic lupus erythematosus, SLE systemic lupus erythematosus, IFN interferon, M module
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Table 3 Differences across subject groups with normal versus high IFN-score
iSLE SLE
IFN normal (n = 14) IFN high (n = 14) p IFN normal (n = 21) IFN high (n = 18) p
Female gender, n (%) 9 (64) 11 (79) 0.40 15 (71) 17 (94) 0.06
Age (years) 50 (25–58) 33 (23–83) 0.10 43 (22–76) 42 (19–74) 0.95
Disease duration (years) 1.9 (0.4–3.4) 1.1 (0.1–4.6) 0.57 2.7 (0.52–6.8) 3.4 (0.7–6.8) 0.61
ACR criteria 3 (1–3) 3 (2–3) 0.70 4 (3–9) 5 (2–8) 0.79
SLICC criteria 3 (2–3) 3 (2–4) 0.70 5 (4–8) 6 (3–9) 0.65
Cumulative criteria
Clinical, n (%)
Skin involvement 4 (29) 8 (57) 0.13 7 (33) 14 (78) 0.006
Photosensitivity 1 (7) 2 (14) NA 4 (19) 5 (28) 0.52
Arthritis 5 (36) 1 (7) 0.07 9 (43) 9 (50) 0.66
Alopecia 0 0 NA 0 (0) 5 (28) 0.01
Ulcera 1 (7) 0 (0) NA 4 (19) 2 (11) 0.49
Hematologic 5 (36) 5 (36) 0.47 13 (62) 13 (72) 0.50
Serositis 2 (14) 0 (0) NA 6 (29) 3 (17) 0.38
Renal 0 0 NA 9 (43) 4 (22) 0.17
Neurologic 1 (7) 0 (0) NA 1 (5) 1 (6) NA
Immunologic, n (%)
Anti-dsDNA 6 (43) 3 (1) 0.23 17 (81) 15 (83) 0.85
Anti-SSA 5 (36) 8 (57) 0.37 5 (24) 8 (44) 0.18
Anti-Smith 0 2 (14) NA 1 (5) 5 (28) 0.05
Decreased complement 1 (7) 3 (21) NA 13 (62) 12 (67) 0.47
aPL 3 (21) 4 (29) 0.52 12 (57) 5 (28) 0.18
Medication use
HCQ 5 (36) 4 (29) 0.67 19 (91) 14 (78) 0.27
NSAIDS 4 (29) 4 (29) 0.90 2 (10) 5 (28) 0.16
Prednisolon 8 (38) 4 (22) 0.28
Azathioprine 5 (24) 1 (6) 0.12
MMF 5 (24) 5 (28) 0.78
SLEDAI 0 (0–6) 1.5 (0–4) 0.40 0 (0–4) 2 (0–4) 0.03
Serological values
ESR (mm/h) 10 (3–51) 25 (6–49) 0.004 12 (3–96) 18 (4–57) 0.08
Hb (mmol/) 8.3 (7.0–9.4) 8.0 (7.0–9.4) 0.19 8 (6.2–9.8) 78.0 (7.3–9.4) 0.95
Leukocytes (×109/L) 6.8 (2.6–9.2) 5.6 (2.8–7.5) 0.09 6.8 (2.3–11.9) 5.0 (3.0–7.7) 0.04
Lymphocytes (×109/L) 1.7 (0.7–3.2) 1.3 (0.5–2.5) 0.33 1.2 (0.3–3.1) 1.2 (0.7–2.3) 0.84
Monocytes (×109/L) 0.5 (0.4–0.9) 0. 4 (0.2–0.7) 0.06 0.5 (0.3–1.1) 0.5 (0.3–0.7) 0.60
Neutrophils (×109/L) 3.5 (1.5–6.3) 3.4 (1.4–4.9) 0.16 4.1 (1.8–11.0) 2.9 (1.9–5.5) 0.03
Thrombocytes (×109/L) 240 (145–406) 238 (135–353) 0.51 238 (120–369) 2413 (112–322) 0.17
CRP (mg/L) 2.5 (0.3–24) 2.5 (0.5–14) 1.0 2.1 (0.3–12) 1.6 (0.3–37) 0.89
GFR (mL/min) 91 (53–107) 92 (80–121) 0.27 91 (48–123) 92 (68–123) 0.90
ANA titer 80 (40–320) 160 (40–640) 0.07 80 (40–640) 160 (40–640) 0.06
Anti-dsDNA (U/mL) 3 (0–50) 1 (0–42) 0.27 5 (0–149) 13 (0–122) 0.26
SSA (U/mL) 0 (0–240) 123 (0–240) 0.09 0 (0–230) 0 (0–240) 0.14
No. of AutoAb 1 (0–1) 1 (0–3) 0.04 1 (0–2) 1 (0–5) 0.07
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(r = 0.53, p = 0.008), IFN12-score (r = 0.54, p = 0.006),
IFN3-score (r = 0.56, p = 0.005), but not with IP-10
serum levels (r = 0.37, p = 0.073) or MCP-1 serum levels
(r = 0.21, p = 0.34). Additionally, iSLE patients with in-
creased MxA expression in the skin endothelium had in-
creased ANA titers (p = 0.02), an increased number of
different antibodies (p = 0.01), and increased IgG levels
(p = 0.02). The same correlations were found in SLE (see
Additional file 1: Table S4).
Discussion
Research on iSLE is scarce, but is of great importance in
order to better understand the pathophysiology of the
disease and to find diagnostic and prognostic bio-
markers. IFN type I is an important early mediator in
SLE and therefore is worthwhile to investigate in pa-
tients with iSLE. In this study, IFN gene expression was
increased in 50% of iSLE patients and correlated with
ESR, low complement, IgG, and the number of different
Table 3 Differences across subject groups with normal versus high IFN-score (Continued)
iSLE SLE
IFN normal (n = 14) IFN high (n = 14) p IFN normal (n = 21) IFN high (n = 18) p
C3 (g/L) 1.2 (0.98–1.47) 1.0 (0.04–1.40) 0.01 1.09 (0.74–1.37) 0.91 (0.54–1.32) 0.03
C4 (g/L) 0.25 (0.09–0.38) 0.17 (0.07–0.24) 0.002 0.17 (0.05–0.34) 0.14 (0.07–0.22) 0.13
IgG (g/L) 11.9 (7.2–14.0) 15.9 (7.7–25.4) 0.04 11.4 (5.0–14.4) 11.4 (6.2–19.5) 0.50
Medians with range, and p values according to Mann Whitney test are given for continuous values, and numbers with percentages, and p values according to chi-
square test for dichotomous variables. p values < 0.05 are indicated by italic font
Abbreviations: ANA antinuclear antibody, Anti-dsDNA anti-double-stranded DNA, aPL antiphospholipid antibodies, NA not applicable, SLEDAI systemic lupus
erythematosus disease activity index, ESR erythrocyte sedimentation rate, HCQ hydroxychloroquine, NSAID non-steroid anti-inflammatory drug, MMF
mycophenolate mofetil
Fig. 2 Serum levels of IFN-related soluble mediators MxA (a), IP-10 (b), and MCP-1 (c) in the three groups and their correlations with IFN12-score
(d–f) and IFN3-score (g–i) in iSLE and SLE patients. The dotted line represents mean + 2SD of the HC. The percentages represent the proportion
of patients above this line. Abbreviations: HC healthy controls, iSLE incomplete systemic lupus erythematosus, SLE systemic lupus erythematosus,
IFN interferon, MxA myxovirus resistance protein A, IP-10 interferon gamma-induced protein 10, MCP-1 monocyte chemoattractant protein 1
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autoantibody types. As this study was cross-sectional in
nature, no conclusions can be drawn about the predict-
ive value of these findings. However, it is known that
autoantibody diversity substantially increases around the
time point of SLE establishment [28, 29]. Furthermore,
decreased complement and higher IgG reactivity were
previously reported to be associated with progression to
SLE in longitudinal studies on iSLE [10, 30]. Thus, cor-
relation of IFN-score with these factors supports the as-
sumption of a relation with progression to established
disease, although longitudinal follow-up is warranted to
confirm this.
To our knowledge, three other studies have been pub-
lished concerning IFN signature in iSLE patients. Re-
cently, Yusof et al. published results on a 12month
follow-up of patients at risk of developing SLE [13].
They included 118 patients with ANA positivity of at
least 1:80 titer and not more than 1 clinical SLICC cri-
terion. The researchers calculated a two-score system
based on factor analysis, of which IFN score A consists
Fig. 3 Receiver operator characteristic (ROC) curve of a IFN12-score and MxA, b IFN3-score and MxA, c IFN12-score and IP-10, and d IFN3-score
and IP-10. Abbreviations: AUC area under the curve, CI confidence interval, MxA myxovirus-resistance protein A, IP-10 interferon gamma-induced
protein 10
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of IFN genes from module 1.2 and module 3.4, whereas
IFN score B mainly consists of genes from module 5.12.
During the 12month follow-up, 14 (12%) progressed to
SLE and 5 (4%) progressed to primary Sjogren’s disease.
The patients who progressed had higher IFN score A
and B at baseline. Olsen et al. found increased expres-
sion of three IFN-related genes (MX1, OAS1, and IFI27)
in iSLE (defined as meeting 1 to 3 ACR criteria), with p
values around 0.002 compared to healthy controls,
which is quite similar to our results [31]. Percentages of
IFN-high individuals were not mentioned in this study,
and associations between IFN-scores and clinical or
serological symptoms were also not reported. Other
than in our study, iSLE patients who used hydroxy-
chloroquine had lower IFN-scores than treatment-
naïve iSLE patients. Interestingly, this was not the
case in SLE patients on hydroxychloroquine. Further-
more, Li et al. found an upregulation of IFN genes in
50% of iSLE patients, which was associated with
higher levels of ANA and a number of other
Fig. 4 MxA expression in the skin of patients with incomplete systemic lupus erythematosus (iSLE) in comparison with healthy controls (HC) and
SLE patients. Representative MxA stainings of a healthy control (a), an iSLE patient with positive MxA staining (++) of endothelium only (b), and
an iSLE patient with positive MxA staining (++) of both the endothelium, the epidermis, and a hair follicle (c), and an SLE patient with positive
(+++) MxA staining of the endothelium (→), the epidermis (#), a hair follicle, and sweat gland (*) (d). Dot plots of semiquantitive MxA expression
in the skin of all groups are shown for the endothelium (e), epidermis (f), and adnexa (g)
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autoantibodies, including anti-RNP, anti-dsDNA, and
anti-SSA [32]. Our study is in line with these studies,
although we did not find a correlation with all men-
tioned autoantibodies, probably because of limited
sample size.
Remarkably, the percentage of SLE patients with an in-
creased IFN12-score in the current study (46%) was
lower than that reported in the literature, and even
lower than that in iSLE. This is probably attributable to
the fact that all patients had quiescent disease. The pres-
ence of the IFN signature is associated with cross-
sectional disease activity and levels of anti-dsDNA [33].
At the time of blood withdrawal, 15% of the SLE patients
had no detectable ANA anymore, and only half of the
patients who previously expressed anti-dsDNA still had
increased titers of this autoantibody. Also, a negative
correlation between IFN expression and time from last
disease flare was found in one study, which suggests that
IFN signature may be less expressed during disease
course [34]. Another explanation for different IFN ex-
pression findings may be the lack of standard procedures
for determining IFN signature. In literature, different
genes, methods, and biological substances have been de-
scribed for measuring IFN gene expression. In order to
improve comparability with previous studies, we calcu-
lated an interferon score based on 3 IFN genes (IFI44L,
LY6E, and MX1) that are among the most frequently
tested in SLE patients [20]. Upon using this score, 51%
of SLE patients were positive, which is in line with other
studies.
Furthermore, we analyzed genes from all three known
interferon-related modules, as published by Chaussabel
et al. [19]. In a previous study in SLE patients, only mod-
ule 1.2 was stable over time, suggesting that this module
best reflects the presence of SLE [20]. In the current
study, IFN1.2 genes were more often upregulated than
IFN3.4 and IFN5.12 genes. Longitudinal analysis will
have to point out if distinguishing these modules is of
predictive value.
It is important to report that 3 of the 22 healthy con-
trols (14%) had ANA titers ≥ 1:80 (2 subjects had titers
of 1:80, nuclear pattern, and coarsely speckled, and 1
subject had a titer of 1:160, coarsely speckled). The
values of the IFN12-scores of these subjects were 3.10,
− 4.03, and − 4.97. As the IFN-score reflects the number
of standard deviations relative to the mean of the control
group, only one of these subjects had higher IFN expres-
sion than the mean of the healthy controls; however,
some ANA-negative healthy controls had higher IFN-
scores. Also, when comparing ANA-positive healthy
controls with ANA-negative healthy controls, the values
of complement and IgG were not clearly different.
Therefore, we do not expect that ANA positivity in our
control group influenced the outcomes of this study.
Hydroxychloroquine (HCQ) is the backbone of SLE
treatment, and its effect is assumed to be mainly based
on blockade of TLR7 and 9, which prohibits production
of IFN-alpha by pDCs [35]. There is some evidence for
delayed onset of SLE after starting treatment with this
drug [36]. In the current study, IFN expression levels
were not different among patients using HCQ. Our find-
ings are in contrast with the results of Olsen et al. who
observed markedly lower IFN gene expression in iSLE
patients using HCQ [31]. This difference can possibly be
explained by other disease characteristics of the patients
on this medication. Ideally, iSLE patients will be longitu-
dinally followed before and after initiation of HCQ, in
order to investigate the direct effect on IFN expression.
Analysis of IFN-related genes is time-consuming and
therefore not ideal for clinical practice. Therefore, in this
study, interferon-related mediators were measured. MxA
was already shown to correlate strongly with IFN gene
expression levels in patients with Sjögren’s disease and
in SLE [37]. In this study, MxA indeed correlated
strongly with IFN-scores in both iSLE and SLE, with an
impressive AUC of 0.94, and also correlated with the
same clinical and serological parameters. MxA thus in-
deed appears to be a suitable and accurate surrogate
marker for IFN type I gene expression.
Also, two other IFN-related chemokines were mea-
sured in iSLE and linked to clinical and serological fea-
tures. These chemokines, other than MxA, which should
be analyzed in whole blood, were tested in serum. Levels
of IP-10-which are induced by IFN-gamma—a type II
interferon—have previously been shown to be increased
in SLE patients and to correspond longitudinally with
disease flares [38]. This chemokine is also of interest as
it appeared to be significantly increased in serum of SLE
patients compared to pre-symptomatic individuals [22,
39, 40]. In the current study, IP-10 was increased in ap-
proximately one third of iSLE patients and corresponded
with the number of classification criteria and hypocom-
plementemia. Furthermore, IP-10 levels correlated with
the IFN12-score, but not as strong as MxA. However,
the role of this chemokine in the pathogenesis of SLE is
not completely understood and longitudinal results
should be awaited to validate its predictive value for SLE
progression. MCP-1 was not increased in iSLE, nor in
SLE, neither did it correspond with disease features.
MCP-1 hence does not seem to be a suitable biomarker
in iSLE.
To test IFN expression in the skin, MxA staining was
performed in unaffected, non-sun-exposed skin biopsies.
MxA is strongly expressed in cutaneous lupus lesions
and was previously shown to co-localize with effector
lymphocytes [41]. Also, the unaffected SLE skin has been
shown to express MxA [42]. In the current study, ap-
proximately one third of iSLE and SLE patients
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expressed MxA in skin endothelium, which correlated
with whole blood MxA levels and IFN-scores. Only a
small percentage (10%) showed positive MxA staining of
the epidermis and adnexa, but this is still a remarkable
finding given the fact that it concerns the unaffected
skin. Interestingly, these structures were only positive
when MxA was also expressed in the endothelium,
which could imply that circulating autoantigens initially
activate IFN production in the skin endothelium and not
in the epidermis itself. The actual clinical relevance of
MxA expression in unaffected skin cannot be elucidated
by our findings. Larger sample sizes and longitudinal
follow-up could shed more light on this subject.
There are some limitations to this study. First, most
patients were Caucasian, and thus, the results might not
be applicable for other ethnic populations. Also, sample
size was limited, mainly due to low prevalence of lupus
in general and the strict inclusion criteria for iSLE.
Conclusions
In summary, IFN upregulation is present in half the pa-
tients with iSLE and correlates with decreased comple-
ment, IgG, and autoantibody diversity. These serological
features are all associated with increased risk of develop-
ing more severe disease in SLE patients. IFN-induced
MxA was found to be expressed in the unaffected skin
of approximately one third of iSLE patients and was as-
sociated with the same serological features. These find-
ings provide further evidence that iSLE patients with
increased IFN type I expression could be at higher risk
for developing complete SLE. Longitudinal data, how-
ever, should confirm this hypothesis.
Finally, whole blood MxA levels correlated strongly
with IFN-scores and could be a suitable and easily ap-
plicable surrogate marker for IFN gene expression.
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